menu
    • menu
    [{"orgOrder":0,"company":"Luminarie","sponsor":"TaiGen Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Nemonoxacin","moa":"Topoisomerase II","graph1":"Infections and Infectious Diseases","graph2":"Approved","graph3":"Luminarie","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Luminarie \/ Luminarie","highestDevelopmentStatusID":"12","companyTruncated":"Luminarie \/ Luminarie"}]

    Find Clinical Drug Pipeline Developments & Deals by Luminarie

    Menu

    Luminarie

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Luminarie

                            Australia arrow
                            American Pharma Summit
                            Not Confirmed

                            Luminarie

                            Australia arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved

                            Recipient : TaiGen Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            TaiGen Out-Licensed Taigexyn® to Luminarie Canada for Canada, Australia and New Zealand

                            Details : Under the terms of the agreement, Luminarie will be responsible for the development, registration and commercialization of Taigexyn® in the territory and assume all associated costs.

                            Brand Name : Taigexyn

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            September 30, 2020

                            Lead Product(s) : Nemonoxacin

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved

                            Recipient : TaiGen Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth